Moderna shares soar on trial data from melanoma vaccine

Cambridge drugmaker Moderna Inc. gained billions in market cap Tuesday morning after it announced that a trial of 157 patients with melanoma showed its experimental drug helped reduce the risk of recurrence or death by 44%.